Insider Transactions in Q1 2022 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 07
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.45%
|
$0
$0.39 P/Share
|
|
Feb 01
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.93%
|
$0
$0.3 P/Share
|
|
Feb 01
2022
|
Jennifer K. Moses CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.97%
|
$6,999
$3.95 P/Share
|
|
Jan 05
2022
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,445
-2.21%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Jennifer K. Moses CFO |
SELL
Open market or private sale
|
Direct |
1,445
-3.91%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
James S. Hanson General Counsel |
SELL
Open market or private sale
|
Direct |
1,445
-5.35%
|
$14,450
$10.61 P/Share
|
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
34,125
-12.77%
|
$341,250
$10.41 P/Share
|
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,000
+14.68%
|
-
|
|
Jan 03
2022
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
|
Jan 03
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+15.52%
|
-
|
|
Jan 03
2022
|
Jennifer K. Moses CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.49%
|
-
|
|
Jan 03
2022
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
|
Jan 03
2022
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+49.92%
|
-
|
|
Jan 03
2022
|
James S. Hanson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+30.77%
|
-
|